Payment overview · 2025
General Payments
$2,100.03
22 reported records · 6 companies
Healthcare provider profile · identity verified
Jay Robert Silverstein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · COVINGTON, LA · NPI 1124241203
Verified facts
What the public records show
CMS Open Payments records show Jay Robert Silverstein, M.D. received $2,100.03 in general payments during 2025 across 22 reported records.
Boston Scientific Corporation accounted for 73.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,545.48 | 73.6% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $318.03 | 15.1% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$153.25 | 7.3% | 7 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $43.33 | 2.1% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $20.28 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.66 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,147.09 | 3 |
| Food and Beverage | $952.94 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $1,520.43 | 5 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $148.23 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $137.07 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $101.82 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $40.77 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $5.67 | 1 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $4.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 182 |
| Metoprolol Succinate | Metoprolol Succinate | 587 | 157 |
| Eliquis | Apixaban | 413 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 320 | 96 |
| Furosemide | Furosemide | 319 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 85 |
| Lisinopril | Lisinopril | 277 | 70 |
| Losartan Potassium | Losartan Potassium | 254 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 44 |
| Carvedilol | Carvedilol | 176 | 51 |
| Ezetimibe | Ezetimibe | 133 | 39 |
| Xarelto | Rivaroxaban | 133 | 25 |
| Bumetanide | Bumetanide | 129 | 35 |
| Ranolazine Er | Ranolazine | 126 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 34 |
| Sotalol | Sotalol Hcl | 115 | 24 |
| Alprazolam | Alprazolam | 108 | 26 |
| Potassium Chloride | Potassium Chloride | 108 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 26 |
| Ramipril | Ramipril | 104 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 20 |
| Repatha Sureclick | Evolocumab | 98 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 24 |
| Nitroglycerin | Nitroglycerin | 89 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 26 |
| Spironolactone | Spironolactone | 88 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 25 |
| Entresto | Sacubitril/Valsartan | 81 | 16 |
| Temazepam | Temazepam | 77 | 13 |
| Propafenone Hcl | Propafenone Hcl | 75 | 15 |
| Clonidine Hcl | Clonidine Hcl | 72 | 14 |
| Metolazone | Metolazone | 71 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | 19 |
| Warfarin Sodium | Warfarin Sodium | 67 | 14 |
| Atenolol | Atenolol | 65 | 18 |
| Midodrine Hcl | Midodrine Hcl | 60 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 21 |
| Metformin Hcl | Metformin Hcl | 56 | 14 |
| Irbesartan | Irbesartan | 54 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 13 |
| Simvastatin | Simvastatin | 46 | 13 |
| Valsartan | Valsartan | 42 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 36 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 13 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Gabapentin | Gabapentin | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Verquvo | Vericiguat | 28 | suppressed |
| Omeprazole | Omeprazole | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Droxidopa | Droxidopa | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,100.03 · 22 records | Boston Scientific Corporation | Assure WCD, COREVALVE EVOLUT R, INSPIRE, LINQ II, MICRA, PASCAL, SAPIEN 3 Ultra RESILIA, SELECTSECURE, WATCHMAN, WATCHMAN FLX, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error